APO Research
Talk to an analyst

APO RESEARCH · REPORT

Irritable Bowel Syndrome (IBS)

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.

Selected research

Market Outlook & Growth Opportunities

Global Irritable Bowel Syndrome (IBS) Market Outlook and Growth Opportunities 2026

26 December 2025190 pages

Choose your research edition.

Industry ResearchIrritable Bowel Syndrome (IBS) Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Irritable Bowel Syndrome (IBS) Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Irritable Bowel Syndrome (IBS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Irritable Bowel Syndrome (IBS) Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Irritable Bowel Syndrome (IBS) Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.

North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.

This report provides an overview of the global Irritable Bowel Syndrome (IBS) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Irritable Bowel Syndrome (IBS) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Irritable Bowel Syndrome (IBS) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Irritable Bowel Syndrome (IBS) market.

Irritable Bowel Syndrome (IBS) Segment by Company

Bausch Health

Allergan

Takeda

Sucampo Pharmaceuticals (Mallinckrodt)

Sebela Pharmaceuticals Inc

Astellas Pharmaceuticals

Irritable Bowel Syndrome (IBS) Segment by Type

IBS-D Drug

IBS-C Drug

Others

Irritable Bowel Syndrome (IBS) Segment by Application

Women

Men

Irritable Bowel Syndrome (IBS) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Irritable Bowel Syndrome (IBS) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Irritable Bowel Syndrome (IBS) key companies, revenue, market share, and recent developments.

3. To split the Irritable Bowel Syndrome (IBS) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Irritable Bowel Syndrome (IBS) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Irritable Bowel Syndrome (IBS) significant trends, drivers, influence factors in global and regions.

6. To analyze Irritable Bowel Syndrome (IBS) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome (IBS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome (IBS) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome (IBS).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Irritable Bowel Syndrome (IBS) industry.

Chapter 3: Detailed analysis of Irritable Bowel Syndrome (IBS) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Irritable Bowel Syndrome (IBS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Irritable Bowel Syndrome (IBS) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Irritable Bowel Syndrome (IBS) Industry Trends Table 2. Irritable Bowel Syndrome (IBS) Industry Drivers Table 3. Irritable Bowel Syndrome (IBS) Industry Opportunities and Challenges Table 4. Irritable Bowel Syndrome (IBS) Industry Restraints Table 5. Global Irritable Bowel Syndrome (IBS) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Irritable Bowel Syndrome (IBS) Revenue Share by Company (2021-2026) Table 7. Global Irritable Bowel Syndrome (IBS) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Irritable Bowel Syndrome (IBS) Key Company Manufacturing Base & Headquarters Table 9. Global Irritable Bowel Syndrome (IBS) Company, Product Type & Application Table 10. Global Irritable Bowel Syndrome (IBS) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Irritable Bowel Syndrome (IBS) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of IBS-D Drug Table 15. Significant Companies of IBS-C Drug Table 16. Significant Companies of Others Table 17. Global Irritable Bowel Syndrome (IBS) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type (2021-2026) Table 21. Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Women Table 23. Significant Companies of Men Table 24. Global Irritable Bowel Syndrome (IBS) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application (2021-2026) Table 28. Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application (2027-2032) Table 29. Global Irritable Bowel Syndrome (IBS) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Irritable Bowel Syndrome (IBS) Sales Value Share by Region (2021-2026) Table 32. Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Irritable Bowel Syndrome (IBS) Sales Value Share by Region (2027-2032) Table 34. Global Irritable Bowel Syndrome (IBS) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Irritable Bowel Syndrome (IBS) Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Irritable Bowel Syndrome (IBS) Sales Value Market Share by Country (2021-2026) Table 37. Global Irritable Bowel Syndrome (IBS) Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Irritable Bowel Syndrome (IBS) Sales Value Market Share by Country (2027-2032) Table 39. Bausch Health Company Information Table 40. Bausch Health Business Overview Table 41. Bausch Health Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Bausch Health Irritable Bowel Syndrome (IBS) Product Portfolio Table 43. Bausch Health Recent Development Table 44. Allergan Company Information Table 45. Allergan Business Overview Table 46. Allergan Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Allergan Irritable Bowel Syndrome (IBS) Product Portfolio Table 48. Allergan Recent Development Table 49. Takeda Company Information Table 50. Takeda Business Overview Table 51. Takeda Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Takeda Irritable Bowel Syndrome (IBS) Product Portfolio Table 53. Takeda Recent Development Table 54. Sucampo Pharmaceuticals (Mallinckrodt) Company Information Table 55. Sucampo Pharmaceuticals (Mallinckrodt) Business Overview Table 56. Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product Portfolio Table 58. Sucampo Pharmaceuticals (Mallinckrodt) Recent Development Table 59. Sebela Pharmaceuticals Inc Company Information Table 60. Sebela Pharmaceuticals Inc Business Overview Table 61. Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product Portfolio Table 63. Sebela Pharmaceuticals Inc Recent Development Table 64. Astellas Pharmaceuticals Company Information Table 65. Astellas Pharmaceuticals Business Overview Table 66. Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio Table 68. Astellas Pharmaceuticals Recent Development Table 69. Research Programs/Design for This Report Table 70. Authors List of This Report Table 71. Secondary Sources Table 72. Primary Sources List of Figures Figure 1. Irritable Bowel Syndrome (IBS) Product Image Figure 2. Global Irritable Bowel Syndrome (IBS) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Irritable Bowel Syndrome (IBS) Market Size (2021-2032) & (US$ Million) Figure 4. Global Irritable Bowel Syndrome (IBS) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. IBS-D Drug Image Figure 8. IBS-C Drug Image Figure 9. Others Image Figure 10. Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Irritable Bowel Syndrome (IBS) Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type (2021-2032) Figure 13. Women Image Figure 14. Men Image Figure 15. Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Irritable Bowel Syndrome (IBS) Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application (2021-2032) Figure 18. Global Irritable Bowel Syndrome (IBS) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Irritable Bowel Syndrome (IBS) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Irritable Bowel Syndrome (IBS) Sales Value (2021-2032) & (US$ Million) Figure 21. North America Irritable Bowel Syndrome (IBS) Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Irritable Bowel Syndrome (IBS) Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Irritable Bowel Syndrome (IBS) Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Irritable Bowel Syndrome (IBS) Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Irritable Bowel Syndrome (IBS) Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Irritable Bowel Syndrome (IBS) Sales Value (2021-2032) & (US$ Million) Figure 27. South America Irritable Bowel Syndrome (IBS) Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • IBS-D Drug
  • IBS-C Drug
  • Others
Applications
  • Women
  • Men
Companies covered
  • Bausch Health
  • Allergan
  • Takeda
  • Sucampo Pharmaceuticals (Mallinckrodt)
  • Sebela Pharmaceuticals Inc
  • Astellas Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Irritable Bowel Syndrome (IBS) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Irritable Bowel Syndrome (IBS) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Irritable Bowel Syndrome (IBS) Market Dynamics
  1. 2.1 Irritable Bowel Syndrome (IBS) Industry Trends
  2. 2.2 Irritable Bowel Syndrome (IBS) Industry Drivers
  3. 2.3 Irritable Bowel Syndrome (IBS) Industry Opportunities and Challenges
  4. 2.4 Irritable Bowel Syndrome (IBS) Industry Restraints
3 Irritable Bowel Syndrome (IBS) Market by Company
  1. 3.1 Global Irritable Bowel Syndrome (IBS) Company Revenue Ranking in 2025
  2. 3.2 Global Irritable Bowel Syndrome (IBS) Revenue by Company (2021-2026)
  3. 3.3 Global Irritable Bowel Syndrome (IBS) Company Ranking (2024-2026)
  4. 3.4 Global Irritable Bowel Syndrome (IBS) Company Manufacturing Base and Headquarters
  5. 3.5 Global Irritable Bowel Syndrome (IBS) Company Product Type and Application
  6. 3.6 Global Irritable Bowel Syndrome (IBS) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Irritable Bowel Syndrome (IBS) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Irritable Bowel Syndrome (IBS) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Irritable Bowel Syndrome (IBS) Market by Type
  1. 4.1 Irritable Bowel Syndrome (IBS) Type Introduction
  2. 4.1.1 IBS-D Drug
  3. 4.1.2 IBS-C Drug
  4. 4.1.3 Others
  5. 4.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Type
  6. 4.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2021-2032)
  8. 4.2.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type (2021-2032)
5 Irritable Bowel Syndrome (IBS) Market by Application
  1. 5.1 Irritable Bowel Syndrome (IBS) Application Introduction
  2. 5.1.1 Women
  3. 5.1.2 Men
  4. 5.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Application
  5. 5.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2021-2032)
  7. 5.2.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application (2021-2032)
6 Irritable Bowel Syndrome (IBS) Regional Value Analysis
  1. 6.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Irritable Bowel Syndrome (IBS) Sales Value (2021-2032)
  7. 6.3.2 North America Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Irritable Bowel Syndrome (IBS) Sales Value (2021-2032)
  10. 6.4.2 Europe Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Irritable Bowel Syndrome (IBS) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Irritable Bowel Syndrome (IBS) Sales Value (2021-2032)
  16. 6.6.2 South America Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2025 VS 2032
7 Irritable Bowel Syndrome (IBS) Country-level Value Analysis
  1. 7.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bausch Health
  2. 8.1.1 Bausch Health Company Information
  3. 8.1.2 Bausch Health Business Overview
  4. 8.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Product Portfolio
  6. 8.1.5 Bausch Health Recent Developments
  7. 8.2 Allergan
  8. 8.2.1 Allergan Company Information
  9. 8.2.2 Allergan Business Overview
  10. 8.2.3 Allergan Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Allergan Irritable Bowel Syndrome (IBS) Product Portfolio
  12. 8.2.5 Allergan Recent Developments
  13. 8.3 Takeda
  14. 8.3.1 Takeda Company Information
  15. 8.3.2 Takeda Business Overview
  16. 8.3.3 Takeda Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Takeda Irritable Bowel Syndrome (IBS) Product Portfolio
  18. 8.3.5 Takeda Recent Developments
  19. 8.4 Sucampo Pharmaceuticals (Mallinckrodt)
  20. 8.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Company Information
  21. 8.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Business Overview
  22. 8.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product Portfolio
  24. 8.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
  25. 8.5 Sebela Pharmaceuticals Inc
  26. 8.5.1 Sebela Pharmaceuticals Inc Company Information
  27. 8.5.2 Sebela Pharmaceuticals Inc Business Overview
  28. 8.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product Portfolio
  30. 8.5.5 Sebela Pharmaceuticals Inc Recent Developments
  31. 8.6 Astellas Pharmaceuticals
  32. 8.6.1 Astellas Pharmaceuticals Company Information
  33. 8.6.2 Astellas Pharmaceuticals Business Overview
  34. 8.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio
  36. 8.6.5 Astellas Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst